Matthew de Jonge spent six years obsessing over a simple question: why do hearing aids feel like a burden while glasses feel natural? That frustration birthed Fortell, an AI-powered hearing aid startup that just closed a $163 million funding round led by Founders Fund, Thrive Capital, and Valor Equity Partners.
The hearing aid market operates as one of the most entrenched monopolies in healthcare. Three companies—Sonova, Demant, and GN Store Nord—control roughly 90 percent of the global market. These incumbents have conditioned the industry around expensive devices, clinical fittings, and prolonged adjustment periods. Patients face barriers at every turn: six-figure price tags, mandatory hearing tests, months of adaptation, and social stigma that drives millions to simply abandon their devices after purchase.
Fortell enters this landscape with a different philosophy. The startup builds hearing aids designed for the actual user experience—not the audiologist's convenience. De Jonge's AI stack handles personalization that traditionally required multiple clinical visits. The technology learns from individual hearing patterns and adjusts in real-time, eliminating the months-long fitting process that makes users feel defective rather than helped.
The $163 million round signals serious investor conviction around the category's vulnerability. Founders Fund has backed several healthcare infrastructure plays that challenged established systems. Thrive Capital and Valor Equity bring deep experience in consumer-grade medical devices that prioritize usability over medical establishment gatekeeping. This is not a bet on hearing aid improvement. This is a bet on market transformation.
The timing matters. Recent regulatory changes have opened over-the-counter hearing aid sales in the US, finally breaking the audiologist stranglehold that protected incumbent margins. OTC regulations meant devices could reach consumers without mandatory professional involvement—but most players moving into that space simply made cheaper versions of existing products. Fortell is building something else entirely: a device ecosystem where AI does what human audiologists took months to accomplish.
De Jonge's founding team combined deep domain expertise with outsider perspective. The six-year development cycle suggests serious R&D investment rather than rushed market entry. Early signals point to adoption rates that mirror glasses rather than traditional hearing aids—users actually want to wear them.
The competitive threat extends beyond direct rivals. Companies like Nuheara have explored direct-to-consumer hearing aid models, and companies like Apple explored hearing health integration within existing products like AirPods. Fortell's funding scale suggests investors believe the category can support a dedicated, venture-backed competitor that captures meaningful market share before incumbents respond effectively.
The hearing aid market represents roughly $15 billion globally, growing slowly due to adoption barriers rather than demand constraints. Fortell's approach targets the 48 million Americans with hearing loss who currently avoid traditional aids entirely. That's not incremental growth. That's market expansion.
With $163 million in the bank, Fortell moves from development to scaled manufacturing and distribution. The startup enters a phase where execution determines whether they become a genuine category disruptor or another well-funded entrant that fails to dislodge entrenched players. De Jonge's conviction—spending six years on this problem—suggests he understands the depth of change required to answer that original question about his grandparents.